Pasithea Therapeutics Corp. (KTTA) stock
Close on Nov 13, 2026Market cap $17.44MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Sep 30, 2026
Valuation
- Market cap
- $17.44M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.40
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$24.83M
- EPS, diluted
- -$1.27
- Book value per share
- $1.31
- Diluted shares
- 33M
Trading
- Previous close
- $0.52
- Open
- $0.56
- Day's range
- $0.46 – $0.58
- Volume
- 2,368,383
- Average volume (20 days)
- 1,702,077
- Beta (5 years)
- 1.64
- 52-week range
- $0.28 – $2.06
- RSI (14 days)
- 56.1
- Volatility (1 year)
- 162.8%
- Relative volume
- 4.49×
- WACC
- 13.3%
Market cap history
Month-end market cap since 2021, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.
| Period | KTTA | S&P 500 | Difference | KTTA per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +23.2% | -3.0% | +26.2 pts | ||
| 3 months | +9.2% | -2.8% | +12.0 pts | ||
| Year to date | -59.5% | +11.5% | −71.0 pts | ||
| 1 year | -25.7% | +13.5% | −39.2 pts | ||
| 3 years | -91.6% | +77.7% | −169.3 pts | -56.2% | +21.1% |
| 5 years | -99.0% | +72.6% | −171.6 pts | -60.1% | +11.5% |
Six years at a glance
Fiscal years 2020 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Pasithea Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Update
- Update
- Update
- Update
- Update
About Pasithea Therapeutics
Pharmaceutical Preparations
Pasithea Therapeutics Corp. is a clinical-stage biotechnology company engaged in discovering, researching, and developing therapeutic treatments. Its drug development pipeline primarily focuses on small molecule therapies for RASopathies, tumors driven by the MAPK pathway, and central nervous system disorders. The company's lead therapeutic product candidate is PAS-004, a next-generation macrocyclic MEK 1/2 inhibitor being evaluated for advanced solid tumors and neurofibromatosis type 1, including plexiform neurofibromas. Additionally, the company conducts early-stage research on its PAS-001 program, which targets complement component 4A for schizophrenia.
Company profile, executives and historyPasithea Therapeutics stock: common questions
What is Pasithea Therapeutics's stock price?
KTTA closed at $0.52 on Nov 13, 2026, up 0.40% on the day. Over the past 52 weeks it traded between $0.28 and $2.06.
What is Pasithea Therapeutics's market cap?
Pasithea Therapeutics was worth $17.44M at the close on Nov 13, 2026: the share price times the diluted shares outstanding.
What is KTTA's P/E ratio?
Pasithea Therapeutics lost money over the twelve months to Sep 30, 2026 (diluted EPS -$1.27), so it has no meaningful P/E ratio.
Does Pasithea Therapeutics pay a dividend?
No. Pasithea Therapeutics has not paid a cash dividend over the last twelve months.
How has KTTA stock performed over the past year?
Including dividends, KTTA returned -25.7% over the past year, against +13.5% for the S&P 500.
How many KTTA shares are sold short?
0M shares were sold short at the latest FINRA report, 1.17% of the float, or 1.0 days of average trading volume.
Who are Pasithea Therapeutics's competitors?
Companies most similar to Pasithea Therapeutics by business, industry and size include CMPS, LRMR, PBM, MPLT, RLMD.
See a number that looks wrong?